7.92
4.21%
+0.32
After Hours:
8.10
0.18
+2.27%
Ironwood Pharmaceuticals Inc stock is currently priced at $7.92, with a 24-hour trading volume of 2.52M.
It has seen a +4.21% increased in the last 24 hours and a -10.51% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $7.62 pivot point. If it approaches the $7.90 resistance level, significant changes may occur.
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Ironwood Pharmaceuticals Inc (IRWD) Revenue 2024
IRWD reported a revenue (TTM) of $442.74 million for the quarter ending December 31, 2023, a +7.83% rise year-over-year.
Ironwood Pharmaceuticals Inc (IRWD) Net Income 2024
IRWD net income (TTM) was -$1.00 billion for the quarter ending December 31, 2023, a -672.50% decrease year-over-year.
Ironwood Pharmaceuticals Inc (IRWD) Cash Flow 2024
IRWD recorded a free cash flow (TTM) of $183.15 million for the quarter ending December 31, 2023, a -33.06% decrease year-over-year.
Ironwood Pharmaceuticals Inc (IRWD) Earnings per Share 2024
IRWD earnings per share (TTM) was -$6.51 for the quarter ending December 31, 2023, a -771.13% decline year-over-year.
Ironwood Pharmaceuticals Inc Stock (IRWD) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
John Minardo | Chief Legal Officer |
Mar 08 '24 |
Option Exercise |
0.00 |
32,752 |
0 |
311,975 |
MCCOURT Thomas A | Chief Executive Officer |
Mar 08 '24 |
Option Exercise |
0.00 |
120,298 |
0 |
1,217,948 |
Davis Andrew | SVP, Chief Business Officer |
Mar 08 '24 |
Option Exercise |
0.00 |
37,120 |
0 |
310,756 |
Emany Sravan Kumar | SVP, Chief Financial Officer |
Mar 08 '24 |
Option Exercise |
0.00 |
37,120 |
0 |
338,853 |
Duane Jon R | Director |
Mar 06 '24 |
Buy |
8.70 |
6,920 |
60,204 |
121,028 |
Emany Sravan Kumar | SVP, Chief Financial Officer |
Mar 04 '24 |
Buy |
9.38 |
10,684 |
100,216 |
301,733 |
MCCOURT Thomas A | Chief Executive Officer |
Feb 12 '24 |
Sale |
15.24 |
177,164 |
2,699,979 |
832,774 |
John Minardo | Chief Legal Officer |
Feb 12 '24 |
Sale |
15.24 |
47,380 |
722,071 |
224,796 |
Shetzline Michael | CMO,SVP,Head-Res&Drug |
Feb 12 '24 |
Sale |
15.24 |
38,618 |
588,538 |
340,484 |
Davis Andrew | SVP, Chief Business Officer |
Feb 12 '24 |
Sale |
15.24 |
9,846 |
150,053 |
208,324 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
Zacks Investment Research
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March
Benzinga
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Nasdaq Gains 100 Points Following PCE Data
Benzinga
Tech Stocks Set To Rise Thursday As January Inflation Data Fails To Scare Markets, Small Caps Surge
Benzinga
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
Zacks Investment Research
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, and Macau; and Nicox SA to generate various therapeutics for the treatment of certain ophthalmic conditions, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):